Comparison of [18F]Fluorocholine and [18F]Fluordesoxyglucose for assessment of progression, lung metastasis detection and therapy response in murine 4T1 breast tumor model

Schirmer, Brígida Gomes de Almeida; Araújo, Marina Rios de; Silveira, Marina Bicalho; Pereira, Jousie Michel; Vieira, Lorena Carla; Alves, Clarice Gregório; Mbolela, William Tshisuaka; Ferreira, Andréa Vidal; Silva-Cunha, Armando; Fialho, Sílvia Ligório; Silva, Juliana Batista da; Malamut, Carlos

doi:10.1016/j.apradiso.2018.07.032

Cited by 10 publications

(8 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The radiotracer [ 18 F]FDG has a good sensitivity but limited specificity and there is an overlap with several types of benign breast diseases. The use of other PET tracers that specifically target cancer hallmark processes such as hypoxia ( 18 F-fluoromisonidazole) [27], proliferation ( 18 F-fluorocholine, 18 F-fluorodeoxythymidine) [28] and tumor and microenvironment acidity (pHLIP) [29, 30] may add more diagnostic, predictive and prognostic information [31] and therefore it can be expected that the full potential of PET/MRI is not realized yet.…”

Section: Discussionmentioning

confidence: 99%

A multiparametric [18F]FDG PET/MRI diagnostic model including imaging biomarkers of the tumor and contralateral healthy breast tissue aids breast cancer diagnosis

Leithner

Horvat

Bernard‐Davila

et al. 2019

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose To develop a multiparametric [ 18 F]FDG positron emission tomography/magnetic resonance imaging (PET/MRI) model for breast cancer diagnosis incorporating imaging biomarkers of breast tumors and contralateral healthy breast tissue. Methods In this prospective study and retrospective data analysis, 141 patients (mean 57 years) with an imaging abnormality detected on mammography and/or ultrasound (BI-RADS 4/5) underwent combined multiparametric [ 18 F]FDG PET/MRI with PET/computed tomography and multiparametric MRI of the breast at 3 T. Images were evaluated and the following were recorded: for the tumor, BI-RADS descriptors on dynamic contrast-enhanced (DCE)-MRI, mean apparent diffusion co-efficient (ADCmean) on diffusion-weighted imaging (DWI), and maximum standard uptake value (SUVmax) on [ 18 F]FDG-PET; and for the contralateral healthy breast, background parenchymal enhancement (BPE) and amount of fibroglandular tissue (FGT) on DCE-MRI, ADCmean on DWI, and SUVmax. Histopathology served as standard of reference. Uni-, bi-, and multivariate logistic regression analyses were performed to assess the relationships between malignancy and imaging features. Predictive discrimination of benign and malignant breast lesions was examined using area under the receiver operating characteristic curve (AUC). Results There were 100 malignant and 41 benign lesions (size: median 1.9, range 0.5–10 cm). The multivariate regression model incorporating significant univariate predictors identified tumor enhancement kinetics ( P = 0.0003), tumor ADCmean ( P < 0.001), and BPE of the contralateral healthy breast ( P = 0.0019) as independent predictors for breast cancer diagnosis. Other biomarkers did not reach significance. Combination of the three significant biomarkers achieved an AUC value of 0.98 for breast cancer diagnosis. Conclusion A multiparametric [ 18 F]FDG PET/MRI diagnostic model incorporating both qualitative and quantitative parameters of the tumor and the healthy contralateral tissue aids breast cancer diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

A multiparametric [18F]FDG PET/MRI diagnostic model including imaging biomarkers of the tumor and contralateral healthy breast tissue aids breast cancer diagnosis

Leithner

Horvat

Bernard‐Davila

et al. 2019

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…Consistently, [ 18 F]fluorocholine ([ 18 F]FCH) tracers for PET imaging have been shown to be effective in cancer detection for several malignances [51]. Moreover, [ 18 F]FCH-PET enables monitoring of therapy response during early stages in breast cancer and is better than [ 18 F]FDG-PET for monitoring breast tumor treatment [51]. Additionally, [ 11 C]choline-PET scans in six patients with breast cancer showed that trastuzumab significantly decreased [ 11 C]choline uptake within 1 month after treatment [52].…”

Section: Open Accessmentioning

confidence: 99%

“…As an essential nutrient required for cellular methyl group metabolism, choline uptake reflects membrane lipid synthesis and the proliferation activity of cells. Consistently, [ 18 F]fluorocholine ([ 18 F]FCH) tracers for PET imaging have been shown to be effective in cancer detection for several malignances [51]. Moreover, [ 18 F]FCH-PET enables monitoring of therapy response during early stages in breast cancer and is better than [ 18 F]FDG-PET for monitoring breast tumor treatment [51].…”

Section: Open Accessmentioning

confidence: 99%

“…PET imaging targeting lipid metabolism Several PET radiotracers targeting lipid synthesis [51,52], fatty acid binding [53], or fatty acid uptake [54] have been developed, although their implications in predicting or monitoring breast cancer therapeutic response still need more investigation. As an essential nutrient required for cellular methyl group metabolism, choline uptake reflects membrane lipid synthesis and the proliferation activity of cells.…”

Section: Open Accessmentioning

confidence: 99%

See 1 more Smart Citation

Integrating metabolic reprogramming and metabolic imaging to predict breast cancer therapeutic responses

Liu

Zhou

Song

2021

Trends in Endocrinology & Metabolism

View full text Add to dashboard Cite

Metabolic reprogramming is not only an emerging hallmark of cancer, but also an essential regulator of cancer cell adaptation to the microenvironment. Metabolic imaging targeting metabolic signatures has been widely used for breast cancer diagnosis. However, limited implications have been explored for monitoring breast cancer therapy response, although metabolic plasticity is notably associated with therapy resistance. In this review, we focus on the metabolic alterations upon breast cancer therapy and their potential for evaluating breast cancer therapeutic responses. We summarize the metabolic network and regulatory changes upon breast cancer therapy in terms of cancer pathological and genetic differences and discuss the implications of metabolic imaging with various probes in selecting target beneficiaries for precision treatment. Key metabolic reprogramming of breast cancer in response to therapyReprogramming of glucose metabolism upon breast cancer therapy Drug-resistant breast cancer cells are able to reprogram glucose metabolism to adapt to the stress induced by drug treatment (Figure 1). For example, breast cancer cells resistant to lapatinib, a dual inhibitor of dermal growth factor receptor (EGFR) and HER2, recover the Highlights Reprogramming of metabolic pathways is pivotal for the adaptation and resistance to antitumor treatments in breast cancer.Metabolic changes upon treatment are superior to single timepoint metabolic signals in monitoring breast cancer therapeutic response.Cancer genetic and metabolic heterogeneity need to be fully integrated to precisely predict breast cancer response to different treatments.Metabolic imaging guided usage of anticancer drugs is critical for precise treatment in breast cancer.

show abstract

“…18 F-fluorocholine was documented to be good substrates for the choline kinase and had biodistribution similar to that of choline 23,27,28,30 . 18 F-fluorocholine was also reported to be helpful in breast cancer detection in animal and human studies, 29,31,32 and higher FCH uptake was observed in human epidermal growth factor receptor 2 (HER2)–positive than HER2-negative breast cancers though not attaining statistical significance 32 . However, the diagnostic performance of proton MRS and FCH PET in breast lesion diagnosis has not been reported.…”

mentioning

confidence: 99%

Diagnostic Performance of Proton Magnetic Resonance Spectroscopy and 18F-Fluorocholine PET to Differentiate Benign From Malignant Breast Lesions

Yen

Shih

et al. 2021

Clin Nucl Med

View full text Add to dashboard Cite

Purpose The aim of this study was to evaluate the diagnostic performance of the proton magnetic resonance spectroscopy (MRS) and 18F-fluorocholine (FCH) PET for suspicious breast findings on conventional imaging (mammography and breast ultrasound). Methods From September 2012 to December 2015, 37 women with 39 breast lesions on conventional imaging were enrolled and underwent proton MRS and FCH PET. The MRS parameters of choline signal-to-noise ratio (SNR), choline integral (I(cho)), and the PET parameters including SUVmax in the prone (SUV1) and supine (SUV2) positions were analyzed. Receiver operating characteristic curves with the area under the curve, sensitivity, and specificity under the optimal cutoff points for the different parameters were determined. Results Twenty-three lesions (59%) were malignant, and 16 (41.0%) were benign. The malignant lesions tended to show significantly higher MRS and PET parameters than benign lesions (choline SNR, P = 0.007; I(cho), P = 0.003; SUV1 and SUV2, P < 0.0001). Fair to moderate correlations were noted between the choline SNR and PET parameters (SUV1, Spearman rank correlation coefficient, ρ = 0.477; SUV2, ρ = 0.483), as well as I(cho) and PET parameters (SUV1, ρ = 0.493; SUV2, ρ = 0.549). The SUV2 showed the highest diagnostic performance (area under the curve, 0.918). Using 2.5 as the optimal cutoff point, the SUV2 yields 89.5% sensitivity and 87.5% specificity for differentiating malignant from benign lesions. Conclusion The MRS parameters were fairly to moderately correlated with FCH PET parameters, and both could differentiate malignant from benign breast lesions with SUV2 showing best diagnostic performance.

show abstract

Comparison of [18F]Fluorocholine and [18F]Fluordesoxyglucose for assessment of progression, lung metastasis detection and therapy response in murine 4T1 breast tumor model

Cited by 10 publications

References 40 publications

A multiparametric [18F]FDG PET/MRI diagnostic model including imaging biomarkers of the tumor and contralateral healthy breast tissue aids breast cancer diagnosis

A multiparametric [18F]FDG PET/MRI diagnostic model including imaging biomarkers of the tumor and contralateral healthy breast tissue aids breast cancer diagnosis

Integrating metabolic reprogramming and metabolic imaging to predict breast cancer therapeutic responses

Diagnostic Performance of Proton Magnetic Resonance Spectroscopy and 18F-Fluorocholine PET to Differentiate Benign From Malignant Breast Lesions

Contact Info

Product

Resources

About